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In the past several years Goldman (1, 2), For-
sey et al (3), Domonkos (4), Savitt (5), Marten
et at (6), and others have reported on the success-
ful use of hydroeortisone and other steroids intra-
cutaneously in various dermatoses. Recently
Stoughton (7) listed those dermatoses in which
intralesional injection of steroids might be ex-
pected to be effective—sarcoidosis, necrobiosis
lipoidica diabeticorum, granuloma annulare,
lichen vidal, synovial cysts, xanthomas, keloids,
localized myxedema, resistant plaques of discoid
lupus crythematosus and hypcrtrophic lichen
planus.
When cortisone and ACTH originally became
available for systemic use it was found that very
large, often dangerous, doses were required to
suppress the lesions of psoriasis vulgaris (8) al-
though in adequate dosage they were almost al-
ways beneficial in the acute or crythrodcrmic
variety (9). Prednisolone and prednisonc likewise
were found to be relatively ineffective in psori-
asis (10, 11). Following the introduction of
triamcinolone it was soon found that this com-
pound appeared to have a strikingly greater
efficacy in psoriasis than the previously available
corticostcroids (12, 13, 14). Shelley ct at (15)
found that 36 of 60 patients with psoriasis had
an excellent response to triamcinolonc. Tn 21 pa-
tients they injected 0.05 cc of a sterile suspension
of 1 % triamcinolone in isotonic sodium chloride
into the lesions. In 12 of these 21 patients there
occurred within 48 to 72 hours a sharply defined
area of involution which persisted for weeks.
Control injections done with saline were without
effect. These 12 patients were among those that
responded well to triamcinolonc orally. In 9 pa-
tients in whom there was no local response to the
injection of triamcinolone, there was also a failure
to respond to triamcinolone orally.
We investigated whether there is a consistent
difference in the intralcsional efficacy of various
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cortisone analogues and whether such a "skin
test" would indeed be a practical preliminary
screening procedure in psoriasis in order to ascer-
tain in advance which corticosteroids would be
most likely to prove effective on oral administra-
tion in the particular patient. In addition, we
compared the therapeutic effects of different
cortisone analogues in the same patients.
MATERIALS ANn METHOOS
Twenty-five patients received intralesional in-
jections of 0.05 cc of 2i % suspensions of triam-
cinolonc diacetate, mcthyl-prcdnisolone acetate,
prednisolone acetate and 0.05 cc of normal saline.
In 15 of these patients, 233% hydrocortisone ace-
tate suspension, and in 10, 233% cortisone ace-
tate was also injected. It was found that reading
of the "skin tests" at 1 week was more efficient
than at 48—72 hours because in some cases a
response such as fading of the erythema in the
injected site did not develop until after 1 week.
Wherever possible the skin tests were done in a
single psoriatic plaque large enough to accommo-
date all the selected tests, yet permitting the
individual test sites to be sufficiently separated
from each other to eliminate all possibility of con-
fusion at the time of reading. In some patients
several plaques in similar locations and with
similar appearance were chosen. The sites of in-
jection of the various steroids within the plaques
were purposefully not consistent so that the
physician reading the tests did not have any
knowledge as to which area had been injected
with which steroid ("blind readings"). In grad-
ing the response to the intralesional injections,
both the size of the involuted area and the degree
of clearing vere considered. The responses to the
intralesional injection of the different steroids
were graded from 0 to 4+. In each patient, the
response to intralesionSl injection subsequently
was compared with the effects of oral administra-
tion of one or more of these same steroids.
\\Thilc the intralesional injections were all done
with 233 % suspensions of the various substances,
the orally administered dosages of the various
steroids were based on the assumption that 3 mg.
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of triamcinolone is approximately as effective
systemically as 4 mg. of methylprednisolone
and 5 mg. of prednisolone (16). We realize that
other equivalents have been suggested (15, 17).
Triamcinolone (given to 24 patients) and
methyl-prednisolonc (given to 23 patients) were
principally used systemically, with a random
selection of one or the other as the initial drug.
Prednisolone was given orally to only 4 patients.
Triamcinolone 16 mg., mcthyl-prednisolone 20
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mg. or prednisolone 30 mg. was used as the initial
dosage for a period of one week. If there was im-
provement the steroid was continued, the dosage
being gradually decreased to zero over a 4 to 5
week period even though it might have appeared
clinically that prolonging the therapy at a cer-
tain dose might have resulted in accelerated or
complete clearing. When a recurrence occurred
after the drug was discontinued, another steroid
was given and the speed of the initial response
and the degree and duration of improvement fol-
lowing cessation of treatment to the 2 drugs were
compared. If there was no improvement at the
end of the first week, a change in treatment to
another steroid was made. No topical or other
systemic treatment was used.
RESULTS
Table 1 shows that the response to the intra-
lcsional injection of triamcinolonc was excellent
or good in 20 of 25 cases and that in every in-
stance triamcinolonc was better than or as good
as the other steroids. In 2 cases triamcinolonc
was only slightly effective and in 3 no effect was
noted.
Of 20 patients with excellent or good response
to intralcsional injection of triamcinolonc 17 had
moderate or complete clearing and 2 showed no
improvement when triamcinolonc was given
orally. Of 2 patients with only moderate response
to injection of triamcinolonc 1 had moderate and
the other excellent improvement after oral admin-
istration (see Table 2). Of 3 patients with no re-
sponse to local injection of triamcinolone 2 also
had no improvement and a third showed marked
improvement upon receiving triamcinolonc orally.
TABLE 2
Intralesional injection and oral administration
of triameino lone
Response to Intralesional
Injection
Response to Oral Administration
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1511-
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ment
Mod-
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Table 3 indicates that of 5 patients with a
marked response to injection of methyl-predniso-
lone 3 responded well and 2 did not improve upon
oral usc of the same steroid. Seven of 13 patients
with a moderate response to local injection of
mcthyl-prcdnisolone responded well to its oral
administration, while the others did not respond.
Of 7 patients who failed to respond to local injec-
tion of methyl-prednisolone, 2 improved and 4
did not improve after its systemic use.
Table 4 indicates that 16 of 25 patients did not
respond to the intralesional injection of predniso-
lone. Only 1 responded well while the remaining 8
had a poor response. Four patients (including the
one with the marked local response) received
prednisolonc orally with no improvement.
Twenty-three psoriatic patients were treated
systemically with both triameinolonc and
methyl-prednisolone and the responses compared.
Four of the 23 patients did not respond to triam-
TABLE 3
Intralesional injection and oral administration of
met hyl-predniso lone
Response to Intralesional
Injection
Response to Oral Administration
Mrkedim-
prove-
ment
Mod-
erate
•im-
prove-
ment
No
im-
prove-
ment
Methyl-
pred-
nisslone
°j'
Marked involution,
5 patients
Moderate involution,
13 patients
No involution,
7 patients
1
3
1
2
4
1
2
5
4
0
1
1
TABLE 4
Intralesionat injection and oral administration
of prednisolone
Response to Intralesional
Injection
Marked involution,
1 patient
Moderate involution,
8 patients
No involution,
16 patients
Response to Oral Administration
Marked
im-
prove-
ment
—
—
—
Mod-
erate
•im-
prove-
ment
—
—
—
No
sm-
prove-
ment
—
1
3
?red-
nisolone
not used
orally
1
7
13
274 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
cinolone or methyl-prednisolone orally adminis-
tered. In 4 patients the response was similar. In
14 patients the response to triameinolone was
better than that to methyl-prednisolone while in
1 patient the reverse was true.
All the patients were weighed and their blood
pressures were taken at each visit. No remarkable
changes were noted. In I patient the use of
steroids orally was stopped because of epigastric
pain while on triamcinolonc. Probably due to the
fact that the patients did not receive steroids
systemically for extended periods such side effects
as moon facics, acneform eroption, hypcrtricho-
sis, severe perspiration, etc., were not seen (18).
DIscUsSION
Prior to this study no direct comparison had
been performed in psoriasis with triamcinolone
and other newer corticosteroids with enhanced
anti-inflammatory properties. Our direct com-
parisons showed triamcinolonc to be more
effective than methyl-prednisolone in 14 of 19
cases. Tn 4 patients the response was equivalent,
4 did not respond to either steroid and in only 1
was mcthyl-prednisolone more effective. These
results indicate that even when doses of presump-
tive generally equivalent anti-inflammatory po-
tency are given triamcinolonc is superior to
other eorticosteroids in psoriasis.
The recent study of Shelley et at (15) suggested
that the response of individual patients with
psoriasis to systemically administered triamcino-
lone could be predicted on the basis of their
responses to a "skin test" with triamcinolone.
In our study 85% of patients with a good
response to intralesional injection of triamcino-
lone also responded to this drug by mouth. With
methyl-prednisolone there was no correlation be-
tween response to intralesional injection and
response to oral administration. Our results indi-
cate that, as had been reported by Shelley et at
(15), there is some correlation between response
to intralesional and oral administration of triam-
cinolone but the exceptions to this arc sufficiently
numerous to limit the value of the intralesional
skin test with triamcinolone as a prognostic pro-
cedure for determining the selection of a par-
ticular corticostcroid for oral administration. It
should be noted however that Shelley et at (15)
used a 1 % triamcinolone suspension while we
used a 2 % suspension for intralesional admin-
istration.
The fact that intralesional injection of triam-
cinolone has prevented a recurrence of psoriasis
in injected sites up to over 200 days indicates that
this may well be a highly useful procedure for the
treatment of localized persistent psoriatic plaques.
Concern has frequently been expressed over the
possibility of atrophy resulting from the intra-
cutaneous injection of steroids. No atrophy was
noted in any of the 25 patients who received in-
tralesional injections. However, the amount of
steroid suspension injected in our "skin tests"
was very small when compared with the amounts
that may be required as a therapeutic measure.
SUMMARY
In direct comparisons, orally administered
triamcinolone in the majority of patients with
psoriasis was found to be more effective than
methyl-prednisolone and prednisolone in the
usual dosage relationships of 3-4-5.
The response to the intralesional injection of
triamcinolonc and methyl-prednisolone was com-
pared with the response to the same steroids ad-
ministered systemically in the same patients.
With triameinolone there was a high incidence of
cases with a good response both to local injection
and to oral administration. However, the small
number of cases where there was no correlation
between the response to local injection and to oral
administration throws doubt on the practical
value of this intralesional skin test.
No correlation was found between intra-
lesional and oral response to methyl-predaisolone.
The persistent clearing (up to over 200 days)
of psoriatic patches after intralesional injection f
triamcinolonc in these "skin tests" suggests that
intralesional injection of persistent localized areas
of psoriasis may well be a worthwhile therapeutic
procedure.
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